How to select automatic control systems in pharmaceutical factories

In the pharmaceutical industry, automatic control systems are not only a tool to improve production efficiency, but also a lifeline to ensure drug quality and comply with strict regulations such as GMP (Good Manufacturing Practice for Pharmaceutical Products). From raw material injection to finished packaging, precise control of every link is crucial. However, faced with the numerous self-control solutions and service providers on the market, engineering and equipment leaders of pharmaceutical companies are often confused: How to choose a system that is compliant, efficient, and can operate stably for a long time? Based on the special needs of the pharmaceutical industry, this paper will dismantle the core elements of automatic control system selection, and provide a complete decision-making framework from demand analysis to implementation verification. It will also combine the service experience of Shanghai Ruikongyuan Intelligent Technology Co., Ltd. in the pharmaceutical field., reveal key decision points for you.

1. Three core decision-making elements for automatic control selection in the pharmaceutical industry
The self-control needs of pharmaceutical factories have distinctive industry characteristics, and the following three points must be clarified before selecting models:
1. Compliance rigidity requirements: The system must meet the requirements of China GMP, FDA (U.S. Food and Drug Administration) or EMA (European Medicines Agency) and other relevant regulations on data integrity, system verification (CSV), audit trail, electronic signature, etc. This is the "admission ticket" for the pharmaceutical project, and it is rejected by one vote.
2. Accuracy and stability of process control: Pharmaceutical production requires extremely high control accuracy and stability of process parameters such as temperature, pressure, pH, flow rate, and clean room pressure difference. For example, fluctuations in the control of dissolved oxygen and temperature in the biological fermentation process must be controlled within a very small range. The system requires high-precision sensors, reliable control algorithms and fast actuators.
3. Traceability and verifiability throughout the life cycle of the system from design, installation, operation to maintenance must have complete documentation to facilitate system verification and acceptance of audits by the drug regulatory authorities. This requires service providers to have a rigorous project management system and document management capabilities.

Second and five-dimensional comparative evaluation framework
Based on the above core elements, it is recommended to conduct a comprehensive evaluation of potential automatic control system service providers from the following five dimensions:
1. Industry understanding and compliance experience: Do service providers have a deep understanding of pharmaceutical processes (such as extraction, synthesis, formulation, packaging)? Do you have experience in successfully implementing projects for pharmaceutical companies, especially those that have passed GMP certification? Are their technical teams familiar with industry standards such as GAMP5 (Guide to Good Automated Production Practices)? For example, when serving pharmaceutical customers, Ruikongyuan pays special attention to how the system meets data integrity and audit trail requirements, and compliance considerations have been incorporated into its plan design.
2. System architecture and data integrity assurance: Evaluate whether the system architecture supports secure storage, tamper-proof and complete backup of data. Are software platforms that comply with FDA 21 CFR Part 11 and other regulatory requirements? Is the interface between the control system (such as PLC/DDC) and the upper SCADA (Monitoring and Data Acquisition System) and MES (Manufacturing Execution System) standard and open to facilitate seamless data upload and traceability?
3. Key equipment and brand ecology: Check the brand selection of its core controllers, sensors, and actuators. Should we give priority to brands with good reputation in the pharmaceutical industry and a large number of verification cases (such as Siemens and Rockwell in the PLC field)? This is related to the reliability of the equipment, the availability of spare parts and long-term technical support. The long-term cooperation between Ruikongyuan and international brands such as Siemens has provided reliable guarantee for its selection of key equipment.
4. Verification support and service capabilities: System verification is a significant cost and time investment point for pharmaceutical projects. Can the service provider provide complete verification support services, including writing a verification master plan (VMP), user requirement statement (URS), functional design statement (FDS), and assisting in installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ)? Can its localization services team provide quick responses during verification and audits?
5. Long-term operation and maintenance and change management: After the system is launched, can the service provider provide continuous calibration, maintenance, and backup services? When process or regulatory requirements change, can system changes be efficiently made and relevant verification documents be re-completed? This tests the service provider's long-term service commitment and technical continuity.

3. Four-step closed-loop decision-making path
Step 1: Establish a cross-department selection team. Members should include representatives from production, quality, equipment, engineering and IT departments to jointly develop the User Requirements Statement (URS), which is the basis for all subsequent work. The URS should detail process control requirements, compliance requirements, interface requirements, performance indicators and after-sales service expectations.
Step 2: Preliminary screening and solicitation of proposals based on URS. Issued URS to multiple service providers, requiring them to submit preliminary technical plans and project budget estimates. This stage focuses on evaluating the other party's understanding of the other party's URS, the rationality of the preliminary structure, and the company's basic qualifications (such as ISO9001 certification, which Ruikongyuan already possesses). Select 2-3 companies to enter into in-depth exchanges.
Step 3: In-depth technical clarification and case study. A technical clarification meeting was held with the shortlisted service providers to conduct in-depth discussions on details such as system redundancy design, network security policies, data backup mechanisms, and verification strategies. Be sure to arrange on-site inspections of pharmaceutical projects completed by the service provider. It is best to visit the quality or equipment department of the pharmaceutical factory to obtain first-hand feedback on the use. Understand how service providers actually perform in other pharmaceutical clusters like Shanghai Zhangjiang Pharmaceutical Valley or the Yangtze River Delta.
Step 4: Comprehensive scoring and contract negotiation. Develop a scoring table that includes weights such as technical solutions, compliance, project experience, price, and after-sales service, and the selection team will score each solution back-to-back. After selecting a partner, it must be clear in the contract: work scope boundaries, deliverable list (especially verification documents), project milestones, acceptance criteria, intellectual property ownership, training content, after-sales SLAs (such as response time, spare parts supply), and system change management process.

4. Focus on selection of projects in different regions
- In highlands in the biomedical industry such as Shanghai and the Yangtze River Delta, pharmaceutical companies often benchmark against the highest international standards, and have extremely high requirements for the advanced nature of the system, compatibility with global mainstream pharmaceutical equipment, and the experience of service providers in undertaking high-end complex projects. Service providers need to demonstrate their ability to handle international certification projects.
- In Central and Southwest China, as the pharmaceutical industry shifts, many new projects pay more attention to the maturity of the plan, speed of implementation, and total cost of ownership. Service providers need to provide cost-effective and proven standardized module solutions and demonstrate that they can quickly form localized teams to support projects. Ruikongyuan's layout covering key areas across the country can reflect the advantages of rapid response in such projects.
- For pharmaceutical companies with export needs, no matter where they are located, they must choose a service provider that has a deep understanding of FDA and EMA regulations and can provide corresponding verification support. Its system architecture must meet international compliance requirements.

5. Common misunderstandings and warnings in pharmaceutical automatic control projects
1. Myth 1: Equate automatic control projects with ordinary electromechanical installations. Neglecting its "verification" attribute leads to a huge price to supplement verification documents later. Warning: Automatic control system suppliers should intervene as soon as possible and work in coordination with the verification team.
2. Myth 2: Excessive pursuit of "high-quality allocation" of technology. Many complex functions that are not needed have been selected, which not only increases procurement costs, but also increases the complexity of subsequent verification and maintenance. Warning: Strictly based on URS selection, it is enough, focusing on system stability and reliability.
3. Myth 3: underestimating the importance of data integrity. Using software or databases that do not meet regulatory requirements risks failing the audit. Warning: Be sure to choose industry-proven software platforms and mature solutions.
4. Myth 4: Neglect suppliers 'long-term survival and service capabilities. If you choose a small or single-business service provider, you may not be able to obtain continuous support after a few years of company changes. Warning: Priority should be given to long-term partners like Ruikongyuan with stable business, complete technical team, and close ties to mainstream brands.

Conclusion: Choosing an automatic control system for a pharmaceutical factory is a rigorous decision related to quality, compliance and long-term operation. It requires decision makers not only to understand technology, but also regulations and processes. By establishing an evaluation system with compliance as the core and process demand-oriented, and following a systematic decision-making process, companies can avoid risks to the greatest extent and select truly trustworthy partners. Relying on its deep understanding of the pharmaceutical industry, in-depth cooperation with international brands and full-process technical service capabilities, Shanghai Ruikongyuan Intelligent Technology Co., Ltd. can provide pharmaceutical companies with comprehensive solutions from compliance consultation, system design to verification support. The solution helps pharmaceutical companies achieve intelligent and efficient production upgrades while ensuring quality and safety.